Over the past 20 years, the concept of mammalian autophagy as a nonselective degradation system has been repudiated, due in part to important discoveries in neurodegenerative diseases, which opened the field of selective autophagy. Protein aggregates and damaged mitochondria represent key pathological hallmarks shared by most neurodegenerative diseases. The landmark discovery in 2007 of p62/SQSTM1 as the first mammalian selective autophagy receptor defined a new family of autophagy-related proteins that serve to target protein aggregates, mitochondria, intracellular pathogens and other cargoes to the core autophagy machinery via an LC3-interacting region (LIR)-motif. Notably, mutations in the LIR-motif proteins p62 (SQSTM1) and optineurin (OPTN) contribute to familial forms of frontotemporal dementia and amyotrophic lateral sclerosis. Moreover, a subset of LIR-motif proteins is involved in selective mitochondrial degradation initiated by two recessive familial Parkinson's disease genes. PTEN-induced kinase 1 (PINK1) activates the E3 ubiquitin ligase Parkin (PARK2) to mark depolarized mitochondria for degradation. An extensive body of literature delineates key mechanisms in this pathway, based mostly on work in transformed cell lines. However, the potential role of PINK1-triggered mitophagy in neurodegeneration remains a conundrum, particularly in light of recent in vivo mitophagy studies. There are at least three major mechanisms by which mitochondria are targeted for mitophagy: transmembrane receptor-mediated, ubiquitin-mediated and cardiolipin-mediated. This review summarizes key features of the major cargo recognition pathways for selective autophagy and mitophagy, highlighting their potential impact in the pathogenesis or amelioration of neurodegenerative diseases.
Cellular quality control and neurodegeneration
Protein aggregates and damaged mitochondria represent key pathological hallmarks shared by most neurodegenerative diseases. From the α-synuclein-containing Lewy bodies and Lewy neurites in Parkinson's disease (PD) to beta-amyloid plaques or neurofibrillary tangles of tau in Alzheimer's disease (AD), these pathological aggregates are highlighted by immunohistochemistry for ubiquitin (Chu et al., 2000) . As polyubiquitination represents a classic signal for protein degradation by the ubiquitin-proteasome system, the accumulation of ubiquitinated aggregates was thought to reflect proteasomal failure in neurodegeneration (Moore et al., 2003; Ross and Pickart 2004) . The proteasomal system classically degrades soluble, short-lived proteins that can be unfolded to pass inside the cylindrical proteasome structure, which may limit its ability to handle aggregated proteins. The autophagy-lysosomal system represents another major quality control system, which is capable of degrading both protein aggregates and organelles such as mitochondria (Ashford and Porter 1962; Elmore et al., 2001; Fortun et al., 2003; Ravikumar et al., 2002; Rideout et al., 2004) . Whereas chaperone-mediated autophagy is also restricted to proteins that can be unfolded (Cuervo, 2004) , macroautophagy (hereafter referred to as autophagy) involves the formation of de novo organelles called autophagosomes (Fig. 1) , which surround and sequester intracellular cargoes of various sizes and compositions. In the last decade, it has become clear that ubiquitin not only regulates proteasomal degradation, but also plays a key role in selective autophagy (Kim et al., 2008; Pankiv et al., 2007; Tan et al., 2007) . Accumulation of ubiquitinated protein aggregates may thus reflect dysregulation of either proteasomal and/or autophagic quality control systems. Impairment in one cellular degradation pathway often results in compensatory upregulation of other pathways, complicating cause and effect relationships (Ding et al., 2003; Xilouri et al., 2009 ). Nevertheless, there is now extensive evidence from both post-mortem analysis of patient brain tissues (Table 1 ) and in experimental models of disease ( Table 2 ) that support a key role for autophagy dysregulation in multiple neurodegenerative diseases. These range from proposed deficits in cargo targeting or impaired completion of autophagy (autophagic stress) to excessive degradation of mitochondria, neuronal atrophy and possibly autophagic cell death [Reviewed in (Boland and Nixon 2006; Cherra III and Chu, 2008; Chu 2006; Harris and Rubinsztein 2012; Liu and Levine 2015) ]. It is evident that autophagy can be dysregulated at multiple steps and the effects of inducing autophagy may be beneficial or detrimental depending on cellular context and downstream factors ( 
